Skip to content
MARKETS / BALCAO / CBIH
BALCAO · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP

Cannabis Bioscience International Holdings, Inc. CBIH

3 fiscal years on record · USD · FY2024 reported · SEC filings only
$303,022
▲ 21.8% YoY
$-548,820
In brief

What this company does

The Company conducts a business generally related to cannabis-related research and education under the trade name Pharmacology University (the “Pharmacology University Business”). The Company conducts clinical trials, some of which may involve cannabis and CBD products as a Sponsor and a CRO under the trade name Alpha Research Institute (the “Alpha Research Business’). The Company plans to manufacture, market and sell CBD products under the name “VitaCookies” (the “CBD Business”). The Company has filed 10 applications for utility patents with the U.S. Patent and Trademark Office (USPTO) and plans to file 10 more. The Company also has an intellectual property portfolio of more than 100 medical formulations for treating conditions including menopause, PTSD, dysbiosis, depression, and Alzheimer’s disease, along with scientific literature and educational audiovisual materials.

Written from the business description in Cannabis Bioscience International Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 22 September 2025. Every sentence was checked against that document before publication.

Growth
USD 303,022.00
Revenue, FY2024 · full 3-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.3 · Net income -0.5
0.2M-0.4M-0.8M202220232024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−181 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -139.1% · Net -181.1%
-100%-200%-300%202220232024
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2024 · dividends + net buybacks

Total assetsUSD 31,880.00
EquityUSD -1.2M
CashUSD 12,952.00
Gross debtUSD 264,092.00
Net debtUSD 251,140.00
Current ratio0.03×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202420232022
Revenue $B0.00.00.0
Operating income $B−0.0−0.0−0.0
EBITDA $B···
Income tax $B·0.00.0
Net income $B−0.0−0.0−0.0
EPS, diluted $−0.00−0.00−0.00
Dividend / sh $···
Payout %···
ROE %···
Shares out B11.6310.4310.06

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 15 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 80 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onOTC market
Incorporated inColorado
Fiscal year endsMay 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2022

Share this section

Download image